Vicarious Surgical (RBOT)
OTHER OTC:RBOT
Want to see RBOT full AI Analyst Report?
Top Page
Vicarious Surgical
(OTC:RBOT)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.53
▼(-71.15% Downside)
Action:UpgradedDate:04/30/26
The score is primarily weighed down by weak financial performance (pre-revenue, ongoing losses, heavy cash burn, and a sharply reduced equity cushion versus debt). Technicals add further pressure with the stock below all major moving averages and negative MACD. Valuation is limited by losses (negative P/E) with no dividend support, and corporate events are notably negative due to the NYSE delisting and OTC transition.
Positive Factors
Improving cash-burn trend
Trailing-twelve-month cash flow remains negative but shows a constructive downtrend versus prior years. A durable reduction in cash outflows extends runway, eases near-term financing pressure and makes execution of commercialization steps and regulatory milestones more feasible without immediate dilutive financing.
Negative Factors
Pre-commercial; zero revenue
The absence of product-derived revenue means the business lacks a repeatable revenue base and remains dependent on successfully commercializing its robotic platform. That structural execution risk increases uncertainty around sustainable margins and long-term cash generation until adoption occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash-burn trend
Trailing-twelve-month cash flow remains negative but shows a constructive downtrend versus prior years. A durable reduction in cash outflows extends runway, eases near-term financing pressure and makes execution of commercialization steps and regulatory milestones more feasible without immediate dilutive financing.
Read all positive factors
Vicarious Surgical (RBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.56M
Dividend YieldN/A
Average Volume (3M)90.39K
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue GrowthN/A
EPS Growth23.21%
CountryUS
Employees123
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,470,228
10 Day Avg. Volume138,739
30 Day Avg. Volume90,387
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap2.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.65
Enterprise Value/Ebitda-0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vicarious Surgical Business Overview & Revenue Model
Company Description
Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ...
How the Company Makes Money
As of publicly available information through its pre-commercial stage, Vicarious Surgical’s planned primary revenue model is to generate revenue from (1) sales (or placement) of its surgical robotic system to healthcare providers and (2) recurring...
Vicarious Surgical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -643.00K | -1.43M | -2.11M | -1.85M | 0.00 | 0.00 |
| EBITDA | -41.22M | -49.54M | -61.12M | -69.19M | 6.47M | -34.80M |
| Net Income | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M |
Balance Sheet | ||||||
| Total Assets | 12.59M | 19.58M | 67.72M | 119.86M | 140.29M | 181.68M |
| Cash, Cash Equivalents and Short-Term Investments | 3.68M | 9.79M | 49.10M | 98.18M | 116.21M | 173.51M |
| Total Debt | 6.82M | 7.79M | 13.79M | 14.83M | 15.69M | 1.34M |
| Total Liabilities | 9.02M | 9.74M | 21.02M | 21.89M | 29.25M | 98.59M |
| Stockholders Equity | 3.57M | 9.84M | 46.70M | 97.97M | 111.05M | 83.09M |
Cash Flow | ||||||
| Free Cash Flow | -39.68M | -45.21M | -50.14M | -63.98M | -66.56M | -34.59M |
| Operating Cash Flow | -39.55M | -45.08M | -49.96M | -62.30M | -61.21M | -33.30M |
| Investing Cash Flow | 32.53M | 32.15M | 6.86M | -45.78M | -5.35M | -1.29M |
| Financing Cash Flow | 5.59M | 5.76M | 8.00K | 44.70M | 9.14M | 192.16M |
Vicarious Surgical Technical Analysis
Negative
1.82
Price Trends
1.19
Negative
1.83
Negative
4.29
Negative
Market Momentum
-0.12
Negative
41.30
Neutral
37.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Negative. The current price of 1.82 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 1.19, and below the 200-day MA of 4.29, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.30 is Neutral, neither overbought nor oversold. The STOCH value of 37.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBOT.
Vicarious Surgical Risk Analysis
Vicarious Surgical disclosed 73 risk factors in its most recent earnings report. Vicarious Surgical reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vicarious Surgical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.29B | -13.83 | -21.49% | ― | 11.08% | -485.09% | |
66 Neutral | $1.62B | 18.63 | 21.07% | ― | 13.60% | 180.19% | |
60 Neutral | $73.30M | 22.00 | 10.27% | ― | 14.21% | ― | |
55 Neutral | $79.03M | -0.69 | -54.99% | ― | 5.09% | 81.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.37B | -18.34 | -27.70% | ― | 29.26% | -7.59% | |
41 Neutral | $3.56M | -0.35 | -247.60% | ― | ― | 23.21% |
* Healthcare Sector Average
RBOT
Vicarious Surgical
0.50
-7.45
-93.71%
LIVN
LivaNova
60.10
23.31
63.36%
XTNT
Xtant Medical Holdings
0.52
0.05
11.51%
INSP
Inspire Medical Systems
56.14
-101.76
-64.45%
OM
Outset Medical
4.27
-6.90
-61.77%
PRCT
PROCEPT BioRobotics
24.04
-28.81
-54.51%
Vicarious Surgical Corporate Events
Shareholder MeetingsStock Split
Vicarious Surgical Shareholders Approve Reverse Stock Split Authorization
Neutral
Apr 8, 2026
On April 8, 2026, Vicarious Surgical Inc. held a special meeting of stockholders at which shareholders representing about 60.68% of the company’s total voting power were present in person or by proxy, establishing a quorum. At the meeting, h...
Business Operations and StrategyDelistings and Listing ChangesFinancial Disclosures
Vicarious Surgical Delisted to OTC as Losses Narrow
Negative
Mar 9, 2026
On March 3, 2026, the New York Stock Exchange moved to suspend and delist Vicarious Surgical’s common stock after the company’s market capitalization fell below the exchange’s $15 million continued listing threshold, and Vicariou...
Business Operations and StrategyExecutive/Board Changes
Vicarious Surgical Implements Executive Salary Reductions, Maintains Incentives
Neutral
Mar 6, 2026
On March 4, 2026, Vicarious Surgical Inc. amended the executive employment agreements of President Adam Sachs and Chief Technology Officer Sammy Khalifa, with both leaders voluntarily agreeing to reduce their annual base salaries to approximately ...
Business Operations and StrategyDelistings and Listing Changes
Vicarious Surgical Announces NYSE Delisting and OTC Transition
Negative
Mar 4, 2026
On March 3, 2026, Vicarious Surgical received notice that the New York Stock Exchange would immediately suspend trading and begin delisting its common stock after the company fell below the exchange’s $15 million average global market capita...
Business Operations and StrategyExecutive/Board Changes
Vicarious Surgical Enhances CEO and CFO Severance Protections
Neutral
Feb 2, 2026
On February 2, 2026, Vicarious Surgical Inc. amended the employment agreement of Chief Executive Officer Stephen From to enhance his severance protections, including up to two years’ worth of salary and target bonus components, extended COBR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.